All patients | hsTnI >16 pg·mL−1 | hsTnI ≤16 pg·mL−1 | p-value | |
Subjects n | 459 | 234 | 225 | |
Age ≥75 years | 155 (33.8%) | 102 (43.6%) | 53 (23.6%) | <0.001 |
Female sex | 241 (52.5%) | 125 (53.4%) | 116 (51.6%) | 0.60 |
Comorbidities | ||||
Chronic heart failure | 59 (12.9%) | 43 (18.4%) | 16 (7.1%) | <0.001 |
Coronary artery disease | 67 (14.6%) | 46 (19.7%) | 21 (9.3%) | 0.002 |
Chronic pulmonary disease | 60 (13.1%), n=458 | 27 (11.6%), n=233 | 33 (14.7%) | 0.33 |
Diabetes mellitus | 65 (14.2%) | 39 (16.7%) | 26 (11.6%) | 0.12 |
Renal insufficiency | 134 (29.2%) | 98 (41.9%) | 36 (16.0%) | <0.001 |
Active cancer | 110 (24.0%) | 45 (19.2%) | 65 (28.9%) | 0.015 |
Symptoms at presentation | ||||
Dyspnoea | 359 (78.6%), n=457 | 190 (81.9%), n=232 | 169 (75.1%) | 0.08 |
Syncope | 53 (11.6%), n=457 | 39 (16.8%), n=232 | 14 (6.2%) | <0.001 |
Altered mental status | 19 (4.1%), n=458 | 11 (4.7%), n=233 | 8 (3.6%) | 0.53 |
Clinical findings at presentation | ||||
Tachycardia | 135 (30.4%), n=444 | 92 (40.7%), n=226 | 43 (19.7%), n=218 | <0.001 |
Hypoxaemia | 74 (19.8%), n=374 | 64 (32.3%), n=198 | 10 (5.7%), n=176 | <0.001 |
Laboratory and imaging markers | ||||
hsTnT ≥14 pg·mL−1 | 259 (60.2%), n=430 | 196 (92.9%), n=211 | 63 (28.8%), n=219 | <0.001 |
NT-proBNP ≥600 pg·mL−1 | 212 (47.5%), n=446 | 168 (75.3%), n=223 | 44 (19.7%), n=223 | <0.001 |
RV/LV diameter ratio ≥1.0 on CTPA | 270 (65.4%), n=413 | 163 (79.5%), n=205 | 107 (51.4%), n=208 | <0.001 |
Risk stratification | ||||
Modified FAST score ≥3 points# | 115 (25.1%) | 113 (48.3%) | 2 (0.9%) | <0.001 |
ESC 2019 algorithm# | <0.001 | |||
Low risk | 58 (12.6%) | 0 (0.0%) | 58 (25.8%) | |
Intermediate-low risk | 265 (57.7%) | 98 (41.9%) | 167 (74.2%) | |
Intermediate-high risk | 136 (29.6%) | 136 (58.1%) | 0 (0.0%) | |
Outcome | ||||
In-hospital adverse outcome | 22 (4.8%) | 19 (8.1%) | 3 (1.3%) | <0.001 |
Catecholamine administration | 15 (3.3%) | 13 (5.6%) | 2 (0.9%) | 0.005 |
Cardiopulmonary resuscitation | 5 (1.1%) | 5 (2.1%) | 0 (0.0%) | 0.027 |
PE-related death | 9 (2.0%) | 8 (3.4%) | 1 (0.4%) | 0.022 |
In-hospital all-cause mortality | 14 (3.1%) | 11 (4.7%) | 3 (1.3%) | 0.036 |
Data are presented as n (%), unless otherwise stated. HsTnI: high-sensitivity troponin I; hsTnT: high-sensitivity troponin T; NT-proBNP: N-terminal pro-brain natriuretic peptide; RV/LV: right/left ventricle; CTPA: computed tomography pulmonary angiography; ESC: European Society of Cardiology; PE: pulmonary embolism. #: Calculation of scores based on hsTnI measurements.